(Reuters) – GlaxoSmithKline said on Tuesday its consumer healthcare venture with Pfizer will be named Haleon, as the British drugmaker confirmed the business will be spun off in mid-2022 as planned after having rejected overtures from Unilever. Last June, GSK announced plans to divest the business, which includes brands such as Sensodyne toothpaste and Advil painkillers, in its biggest shake-up in two decades to focus on its prescription drugs and vaccines business. The British group, which had rejected Unilever’s 50 billion pound ($68 billion) bid for the consumer healthcare business in Decem…